Archives: Search / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011
Aug 26, 2020 Financial and Business Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 fourth quarter and full year ended June 30, 2020. "For both the fiscal 2020 full year and fourth quarter, our... More |
Aug 19, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 fourth quarter and full year on Wednesday, August 26, 2020, after the market closes.... More |
Aug 17, 2020 Lannett Company, Inc. (NYSE: LCI) today announced the Notice of Proposed Settlement and Dismissal with Prejudice of Derivative Action (the "Notice"), a copy of which is attached hereto as an... More |
Aug 17, 2020 --Company Extends Distribution Term for Generic ADVAIR DISKUS®-- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone... More |
Aug 3, 2020 Lannett Company, Inc. (NYSE: LCI) today announced the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, under the companies recently announced interim exclusive supply and... More |
Jul 27, 2020 -- Signs Exclusive U.S. Distribution Agreement with Novitium Pharma -- Lannett Company, Inc. (NYSE: LCI) today announced that it will soon launch Levorphanol Tablets 2 mg, a partnered product. Lannett entered into an exclusive U.S. distribution agreement for... More |
Jul 23, 2020 --Second Product with Strategic Partner, Rivopharm-- Lannett Company, Inc. (NYSE: LCI) today announced that it has launched Mexiletine Hydrochloride Capsules 150 mg, 200 mg and 250 mg, a partnered product. Mexiletine Hydrochloride Capsules is the... More |
Jul 16, 2020 --Lannett to Commence Marketing on August 3, 2020-- Lannett Company, Inc. (NYSE: LCI) and Cediprof, Inc., a part of the Neolpharma Pharmaceutical Group family of companies, today said that the companies have entered into an interim exclusive supply... More |
Jul 13, 2020 Lannett Company, Inc. (NYSE: LCI) today announced a restructuring and cost savings plan. The initiatives include consolidating the research and development (R&D) function into a single location in... More |
Jun 11, 2020 --Company Anticipates Biosimilar Application to be Submitted By End of Calendar Year 2022-- Lannett Company, Inc. (NYSE: LCI) today said that representatives from the company spoke with and received guidance from the U.S. Food and Drug Administration (FDA) on the clinical advancement... More |